Key result
Primary angiosarcoma is linked to a ~50% higher mortality risk than secondary angiosarcoma.
Why the study?
Reliable assessment of angiosarcoma prognostic factors has proven difficult due to disease rarity, study cohort heterogeneity, and a lack of histological confirmation in large registries.
Does primary angiosarcoma have a different overall survival compared to secondary angiosarcoma?
Cohort (n=479)
Yes
Does primary angiosarcoma have a different overall survival compared to secondary angiosarcoma?
Hazard Ratio: 1.5 (95% CI 1.2–1.9)
Absolute Event Rate: 7% vs 21%
Primary angiosarcoma is associated with significantly worse overall survival compared to secondary angiosarcoma, with age over 65, male gender, and lack of surgical treatment also serving as poor prognostic factors.
May guide prognostic counseling in angiosarcoma; leaves open whether primary cases warrant distinct therapies.
Angiosarcoma (AS) is a rare sarcoma of endothelial origin, arising spontaneously (primary AS) or after external damage such as radiation therapy or UV exposure (secondary AS). To date, reliable assessment of prognostic factors has proven difficult, due to disease rarity and heterogeneity of study cohorts. Although large registries provide relatively large AS patient series, these cases often lack histological confirmation. This study aimed to analyze AS prognostic factors in a large nationwide cohort of histologically confirmed cases, established through linkage of clinical data from the Netherlands Cancer Registry and pathology data from the Dutch pathology registry (PALGA). All cases were reviewed by an expert pathologist, showing a 16% discordance rate. Multivariable Cox regression survival analysis among 479 confirmed AS patients revealed remarkably poorer overall survival (OS) for primary AS compared to secondary AS (7 vs 21 months, Hazard ratio (HR) = 1.5; 95% confidence interval (CI) = 1.2-1.9). Age above 65 years, male gender, and no surgical treatment also significantly correlated to worse OS. Overall, OS was relatively poor, with a median of 13 months (95% CI = 10-16 months) and 22% five-year survival rate. With this study, we illustrate AS heterogeneity in clinical behavior and show for the first time better survival for secondary AS compared to primary AS.
No takes yet. Share an insight, caveat, or question.
Weidema et al. (2019) conducted a cohort in Primary and Secondary Angiosarcomas (n=479). Primary angiosarcoma vs. Secondary angiosarcoma was evaluated on Overall survival (HR 1.5, 95% CI 1.2-1.9). Primary angiosarcoma was associated with significantly poorer overall survival compared to secondary angiosarcoma (median 7 vs 21 months; HR 1.5, 95% CI 1.2-1.9).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: